The One Big Beautiful Bill Act (OBBBA), signed on July 4, 2025, did more than restore full immediate expensing for domestic R&D. It also created a narrow retroactive relief window for small businesses that were forced to capitalize their R&D expenses during 2022-2024 under the TCJA amendments to Section 174.
That window closes on July 6, 2026. After that date, the ability to amend prior-year returns and reclaim the full deduction is gone.
This guide walks through the eligibility requirements, the filing process, the Section 280C coordination that trips up many filers, and worked examples showing the potential tax impact. If your company capitalized domestic R&D expenses during 2022-2024 and your average annual gross receipts are $31 million or less, this applies to you.
Small businesses with average annual gross receipts of $31 million or less can file amended returns for 2022, 2023, and 2024 to reclaim full R&D deductions. The deadline is July 6, 2026 — there is no extension provision in the statute.
Before preparing any amended returns, you need to confirm that your company meets the small business threshold for each tax year you intend to amend.
The threshold is based on a three-year average of annual gross receipts for the three tax years preceding the year being amended:
| Tax Year Being Amended | Averaging Period | Your Average Must Be |
|---|---|---|
| 2022 | 2019, 2020, 2021 | $31M or less |
| 2023 | 2020, 2021, 2022 | $31M or less |
| 2024 | 2021, 2022, 2023 | $31M or less |
Gross receipts is defined broadly under Section 448(c). It includes total sales and services, interest, dividends, rents, royalties, and any other income — not net revenue, not taxable income. For a SaaS company, this means total recognized revenue plus any other receipts, before any deductions.
If your company was part of a controlled group or had affiliated entities during the averaging period, you may need to aggregate gross receipts across the group. The $31M threshold applies to the controlled group as a whole, not to individual entities. This is a common oversight that can disqualify otherwise eligible companies.
The retroactive relief applies to all entity types that file US federal income tax returns and had specified R&D expenses capitalized under Section 174 during 2022-2024:
For pass-through entities (S corps and partnerships), the amended return is filed at the entity level, and the corrected income flows through to partners and shareholders on amended K-1s.
Once eligibility is confirmed, the next step is identifying exactly which capitalized expenses qualify for retroactive deduction.
For each tax year (2022, 2023, 2024), gather the schedules that were prepared when the R&D expenses were originally capitalized. These should detail the total specified R&D expenses, the domestic versus foreign split, and the amortization calculations.
Only domestic R&D expenses are eligible for retroactive deduction. Foreign R&D — including expenses incurred by offshore contractors, foreign subsidiaries, or research performed outside the US — remains subject to 15-year amortization and cannot be amended.
For each year, compute the difference between: (a) the full domestic R&D expense and (b) the amount of amortization that was actually deducted on the original return. This differential is the additional deduction you will claim on the amended return.
If you capitalized 2022 R&D and deducted partial amortization in 2023 and 2024, the amended 2022 return will claim the full deduction in 2022 — but the 2023 and 2024 returns must reverse the amortization deductions that were taken in those years for the 2022 capitalized amount. This netting is essential to avoid a double deduction.
The calculation can become complex when R&D expenses from multiple years overlap. For example, your 2024 return may include amortization deductions for R&D capitalized in 2022, 2023, and 2024. When you amend all three years, you need to carefully net the deductions to ensure each dollar of R&D expense is deducted exactly once.
This is the step that catches many filers by surprise. If your company claimed the Section 41 R&D tax credit during any of the years being amended, Section 280C applies and reduces the amount of R&D expenses eligible for full deduction.
Section 280C prevents a double benefit. When a company claims the R&D credit under Section 41, it cannot also deduct the full amount of the same R&D expenses. The coordination rule requires the taxpayer to either:
If you elected the reduced credit on your original return (the more common approach for many companies), the deduction reduction may be minimal. But if you took the full credit without making the reduced credit election, the retroactive deduction will be reduced dollar-for-dollar by the credit amount.
| Scenario | R&D Expenses | Section 41 Credit | 280C Approach | Deductible Amount |
|---|---|---|---|---|
| Reduced credit election made | $1,000,000 | $65,000 (reduced) | Deduction preserved | $1,000,000 |
| No reduced credit election | $1,000,000 | $100,000 (full) | Deduction reduced | $900,000 |
| No R&D credit claimed | $1,000,000 | $0 | No coordination needed | $1,000,000 |
If your original return claimed the full Section 41 credit without the reduced credit election, and you now file a retroactive amended return for additional R&D deductions, the Section 280C reduction must be applied to the amended return. Failing to coordinate this correctly will likely trigger an IRS adjustment.
With the calculations complete, the amended returns can be prepared.
For each tax year being amended, file the appropriate form:
The IRS issued Revenue Procedure 2025-28 specifically for the Section 174 to 174A transition. Key procedural requirements include:
Review the Revenue Procedure in full before filing. The IRS has indicated that claims not following the prescribed format may face processing delays.
The financial impact depends on the volume of domestic R&D expenses, your effective tax rate, and how much amortization was already deducted. Here are two illustrative scenarios.
The exact figures depend on the mid-year convention calculations and any Section 280C adjustments, but the order of magnitude is clear: for a company spending $1.5 million annually on R&D, the three-year refund potential is in the hundreds of thousands of dollars.
A company with $4 million in annual domestic R&D, average gross receipts of $22 million, and operating as a C corporation could see a three-year total refund exceeding $1.5 million — depending on Section 280C coordination and state-level conformity.
A medical device startup that spent $2.5M on domestic R&D annually during 2022-2024 — and capitalized all of it under Section 174 — would have deducted approximately $750K in amortization per year (using the 5-year mid-year convention). Filing retroactive amended returns to claim the full $2.5M deduction each year generates an additional deduction of approximately $1.75M per year, or roughly $370K in federal tax refund per year at a 21% rate. Over three years, that is approximately $1.1M in refunds — capital that can be reinvested into the business.
Based on early guidance from tax practitioners and the IRS, these are the errors most likely to delay or invalidate retroactive claims:
Forgetting to reverse cross-year amortization. When you amend 2022 to take the full deduction, you must also adjust 2023 and 2024 to remove the amortization that was deducted in those years for the 2022 capitalized amount. All amended years must be filed together.
Ignoring Section 280C coordination. If the R&D credit was claimed, the deduction must be reduced accordingly. The IRS will catch this in processing.
Including foreign R&D in the retroactive claim. Only domestic R&D expenses qualify. Foreign expenses remain subject to 15-year amortization.
Missing the July 6, 2026 deadline. The statute is explicit. There is no provision for extensions, late filings, or reasonable cause exceptions for the retroactive claim period.
Not accounting for state tax implications. Many states conform to the federal treatment of R&D expenses, but not all. Some states may require separate amended returns or may not recognize the retroactive deduction.
Filing a retroactive R&D claim is a tactical tax exercise. But it connects to a larger strategic question: do you know the value of the intangible assets your R&D spending creates?
Every dollar of R&D expenditure produces something — a patent, a software feature, a trade secret, a proprietary algorithm, or a process improvement. These are intangible assets that drive your company's valuation even when they do not appear on the balance sheet under traditional accounting standards.
Opagio helps companies track their R&D as intangible capital — mapping expenditures to specific asset categories, measuring the value those assets create, and presenting that value in the context of IAS 38, ASC 730, and the Opagio 12 value driver framework. Whether you are preparing for an exit, raising a funding round, or simply trying to understand what your R&D investment has built, the Opagio Valuator provides the analytical framework to answer that question.
Is there any extension possible beyond July 6, 2026? No. The OBBBA specifies the deadline as one year from the date of enactment (July 6, 2025, the first business day after the July 4 signing). There is no reasonable cause exception or extension provision for the retroactive claim period.
Do I need to file all three years at once? While there is no statutory requirement to file all three amended returns simultaneously, it is strongly recommended. The cross-year amortization netting is easier to manage when all years are prepared together, and it reduces the risk of errors.
What about state taxes? State conformity varies. Some states automatically conform to federal R&D treatment (rolling conformity), while others conform to a fixed date or have their own rules. Check each state where your company files to determine whether separate amended state returns are required.
Ivan Gowan is the Founder and CEO of Opagio. With 25 years in financial technology — including building and scaling technology platforms at IG Group from a £300m to a £2.7bn company — he brings direct experience of how R&D investment creates intangible capital that traditional accounting fails to capture. Meet the team.
The One Big Beautiful Bill Act restored full R&D expensing under new Section 174A for tax years beginning 2025. Small businesses can retroactively reclaim deductions for 2022-2024. Here is what changed, who qualifies, and what the July 6 2026 deadline means for your company.
Read more →R&D spending creates intangible capital that rarely appears on the balance sheet. This article examines the gap between what companies invest in R&D and what their financial statements show, with practical guidance on mapping R&D to intangible asset categories under both US and UK accounting frameworks.
Read more →
Intangible assets now drive over 90% of enterprise value in the modern economy. Yet most businesses struggle to identify, measure, or manage them.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Book a free consultation to see how the Opagio Growth Platform can help your business.